Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Local interferon therapy for melanoma patients

D Ikić1, S Spaventi, I Padovan

  • 1Department of Medicine, Croatian Academy of Sciences and Arts, Zagreb, Croatia.

International Journal of Dermatology
|December 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Managing COVID-19 within and across health systems: why we need performance intelligence to coordinate a global response.

Health research policy and systems·2020
Same author

How can we monitor the impact of national health information systems? Results from a scoping review.

European journal of public health·2019
Same author

Assessment of Prognostic Factors in 102 Patients with Myelodysplastic Syndrome-Osteoblasts are Related to Survival.

Hematology (Amsterdam, Netherlands)·2016
Same author

Anterior versus posterior approach in 3D correction of adolescent idiopathic thoracic scoliosis: a meta-analysis.

Orthopaedics & traumatology, surgery & research : OTSR·2012
Same author

Optically stimulated luminescence in vivo dosimetry for radiotherapy: physical characterization and clinical measurements in (60)Co beams.

Physics in medicine and biology·2011
Same author

Preliminary report on vaccination in Croatia against poliomyelitis with type 1 (CHAT) and type 3 (W-Fox) attenuated polioviruses of Koprowski.

Bulletin of the World Health Organization·2010

Recombinant interferon-alpha 2c (r.IFN alpha 2c) shows promising results for treating advanced melanoma (Clark levels III and IV). Survival rates were significantly higher in patients treated with r.IFN alpha 2c compared to historical controls.

Area of Science:

  • Oncology
  • Immunotherapy

Background:

  • Malignant melanoma incidence is rising globally.
  • Tumor invasion depth is a key prognostic factor in melanoma.
  • Advanced melanoma (Clark levels III and IV) presents a significant clinical challenge.

Purpose of the Study:

  • To evaluate the efficacy of local r.IFN alpha 2c in treating melanoma patients with Clark levels III and IV.
  • To compare survival outcomes between interferon-treated patients and historical control groups.

Main Methods:

  • A study involving 27 patients treated with r.IFN alpha 2c and 4 with human natural leukocyte interferon (HNLI).
  • Local interferon application was employed.
  • Kaplan-Meier and Cox methods were used for statistical analysis, comparing outcomes against historical controls (10 patients with Clark levels III-IV).

Related Experiment Videos

Main Results:

  • Interferon-treated groups (r.IFN alpha 2c) demonstrated higher survival percentages (60% vs. 25% for Clark III/IV, 40% vs. 33% for Clark IV).
  • Statistical analysis at 60 months showed significantly better outcomes in the interferon group (P = 0.0175).

Conclusions:

  • While the control group was not randomized, the results suggest r.IFN alpha 2c is a promising treatment for advanced melanoma (Clark levels III and IV).
  • Further clinical investigation into r.IFN alpha 2c for melanoma is warranted.